Oppenheimer raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $105 and keeps an Outperform rating on the shares. The firm notes Vykat XR sales of $32.7M in its first launch quarter came in line with last month’s pre-announcement. With a U.S. launch trending toward cash-flow positive and EU sales poised to begin next year, Oppenheimer views Soleno as a highly attractive, clean growth story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Reports Strong Q2 2025 Performance
- Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand
- Tyler Van Buren Reaffirms Buy Rating with Increased Sales Projections and Price Target for SLNO
- Soleno Therapeutics price target raised to $121 from $105 at Baird
- Soleno Therapeutics Announces Public Stock Offering